Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura

Blood Transfus. 2014 Oct;12(4):605-7. doi: 10.2450/2014.0246.13.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Benzoates / administration & dosage*
  • Drug Resistance / drug effects*
  • Female
  • Humans
  • Hydrazines / administration & dosage*
  • Middle Aged
  • Purpura, Thrombocytopenic, Idiopathic / blood
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Pyrazoles / administration & dosage*
  • Receptors, Fc / administration & dosage*
  • Recombinant Fusion Proteins / administration & dosage*
  • Thrombopoietin / administration & dosage*

Substances

  • Benzoates
  • Hydrazines
  • Pyrazoles
  • Receptors, Fc
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • romiplostim
  • eltrombopag